Affordable access

Ensuring access to essential medicines for the poorest countries

A staggering two billion people worldwide still lack access to quality medicine and healthcare in 2021. Sanofi aims to change this by ensuring affordable access to medicines for underserved communities, while helping to build sustainable healthcare systems.

Creating a global health unit

As we launch our first ever global social commitment strategy, we are making affordable access our first priority. We are forming Sanofi Global Health, a nonprofit business unit with a remit to donate or sell our medicines at affordable prices in some of the least developed regions of the world. It will be self-financing to ensure it remains sustainable over time, charging just enough to cover operating expenses and product cost without making a profit.

Initially, Sanofi Global Health will operate in the 40 countries with some of the lowest gross domestic product (GDP) per capita, and will offer 30 of our most essential medicines, including treatments for cardiovascular disease, diabetes, tuberculosis, malaria and cancer. We will also work with local health authorities and care providers to build capability and monitor sustainable care systems for diseases that require chronic treatment and complex care.

Supporting people with rare diseases

After 30 years of supporting people with rare diseases, we are formalizing the Sanofi Genzyme access program and will donate at least 100,000 vials of medication for lysosomal storage diseases, a group of rare genetic conditions caused by enzyme deficiencies, every year. That’s enough to treat around 1,000 patients for free in parts of the world where treatment options are limited.

Developing a global access plan

The affordability of our medicines is not the only barrier to access for many people. So too is the speed at which we launch new medicines into the majority of markets. Our goal is to develop a global access plan for all new products, making them available in all chosen markets within two years of launch. This bold ambition will ensure that millions more people receive timely treatment and thousands of lives are saved.

Change the course of malaria

Since 2001, we have pursued a holistic approach to controlling malaria that encompasses the manufacture and supply of medicines as well as a prevention strategy aimed at training healthcare workers to better manage the disease and awareness initiatives to educate the population. In 2050, more than half of the African population will be under 25 years of age, so we have a special focus on reaching children, who can help change the course of malaria for the next generation.

Discover more

COVID-19: Ensuring global access to vaccines

In October 2020, Sanofi and GSK signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines. We intend to make available 200 million doses of our adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities. We support COVAX’s ambition to ensure successful COVID-19 vaccines reach those in need, whoever they are and wherever they live. The partnership with COVAX reflects our long-term commitment to global health and ensures our potential COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.